" class="no-js "lang="en-US"> Aristea Therapeutics - Medtech Alert
Thursday, March 28, 2024
Aristea Therapeutics | Pharmtech Focus

Aristea Therapeutics

About Aristea Therapeutics

Aristea Therapeutics

Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea’s lead program, RIST4721, is currently in Phase 2 clinical development.

Related Story

Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer

August 25 2022

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat […]

Aristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis

March 29 2022

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat […]

Aristea Therapeutics Announces Key Leadership Appointments to Advance its Clinical Pipeline

January 14 2022

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat […]

Aristea Appoints Justin Thacker as Chief Financial Officer

August 24 2021

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat […]

Aristea Completes $63 Million Series B Financing to Accelerate Clinical Development of Novel Immunotherapy Drugs for the Treatment of Orphan Diseases

July 28 2021

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat […]